Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-RAD204 in Metastatic Solid Tumors
NCT06305962Phase 1Recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177lu-rad204 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC) and 5 more, sponsored by Radiopharm Theranostics. Primary endpoints: Safety and tolerability of 177Lu-RAD204 at 6 weeks and Recommended dose(s) of 177Lu-RAD204 for future exploration at 6 weeks. Started Jun 2024; status: recruiting.
02
Drugs
177lu-rad204
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)triple-negative breast cancer (TNBC)cutaneous melanoma (CM)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06305962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305962.